47 patents
Utility
Parathyroid Hormone (PTH) Receptor Antagonists and Uses Thereof
25 May 23
Described herein are compounds that are parathyroid hormone (PTH) receptor modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of PTH receptor activity.
Joseph PONTILLO, Shimiao WANG, Yunfei ZHU
Filed: 29 Sep 22
Utility
Gem-disubstituted Piperidine Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
4 May 23
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 11 Dec 20
Utility
Spirocyclic Piperidine Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
27 Apr 23
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 10 Dec 20
Utility
Somatostatin modulators and uses thereof
21 Mar 23
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 11 Feb 19
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
31 Jan 23
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
Filed: 8 Feb 21
Utility
Somatostatin Modulators and Uses Thereof
26 Jan 23
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 6 Apr 22
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
19 Jan 23
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 30 Oct 20
Utility
Uses of a Somatostatin Modulator for the Treatment of Disease
8 Dec 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Ajay MADAN, Sha Rosa LUO, Alan S. KRASNER
Filed: 24 May 22
Utility
Somatostatin Modulators and Uses Thereof
1 Dec 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Sangdon HAN, Sun Hee KIM, Shimiao WANG, Yunfei ZHU
Filed: 1 Jul 22
Utility
Nonpeptide somatostatin type 5 receptor agonists and uses thereof
25 Oct 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Yunfei Zhu, Shimiao Wang, Mi Chen, Joseph Pontillo
Filed: 10 Aug 20
Utility
Somatostatin Receptor Type 5 Agonist for the Treatment of Hyperinsulinism
13 Oct 22
Provided herein are methods and compositions for the treatment of hyperinsulinism
Christine FERRARA-COOK, Alan S. KRASNER
Filed: 16 Feb 22
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonist for the Treatment of Disease
6 Oct 22
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
Christine FERRARA-COOK, Alan S. KRASNER
Filed: 16 Mar 22
Utility
Crystalline Forms of Somatostatin Modulators
25 Aug 22
Described herein are pharmaceutically acceptable salts of a somatostatin modulator, crystalline forms of the pharmaceutically acceptable salts of the somatostatin modulator, methods of making such salts and crystalline forms, pharmaceutical compositions and medicaments comprising such salts and crystalline forms, and methods of using such salts and crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. REDDY, Yuxin ZHAO, Mahmoud MIRMEHRABI, Alex MAYO, Madhukar KOTA, Uttam DASH, Vijaykumar Umesh NAIK, Praveen Kumar BANDARU, Yuanqing FANG
Filed: 15 Jul 20
Utility
Crystalline Forms of a Somatostatin Modulator
18 Aug 22
Described herein are crystalline forms of 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide, uses of such crystalline forms in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a somatostatin modulator compound.
Yuxin ZHAO, Jayachandra P. REDDY, Lauren MACEACHERN, Samer KAHWAJI, Evans MONYONCHO, Peter MUELLER
Filed: 16 Feb 22
Utility
Somatostatin modulators and uses thereof
16 Aug 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Sangdon Han, Sun Hee Kim, Shimiao Wang, Yunfei Zhu
Filed: 26 Oct 20
Utility
Formulations of a Somatostatin Modulator
12 May 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Gerald BURKE, Ian YATES, Hannah BULOVSKY, Kyle KYBURZ, Clayton TYLER
Filed: 25 Jan 22
Utility
Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof
12 May 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Yunfei ZHU, Shimiao WANG, Mi CHEN, Joseph PONTILLO
Filed: 21 Jan 22
Utility
Formulations of a Somatostatin Modulator
10 Mar 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Gerald BURKE, Ian YATES, Hannah BULOVSKY, Kyle KYBURZ, Clayton TYLER
Filed: 7 Sep 21
Utility
Formulations of a somatostatin modulator
8 Mar 22
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
Filed: 7 Sep 21
Utility
Somatostatin Modulators and Uses Thereof
17 Feb 22
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee KIM, Yunfei ZHU
Filed: 26 Oct 21